TrialHuman vaccines & immunotherapeutics2021

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study.

Asmik Asatryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.